dialysis + transplant Flashcards
3 types of haemodialysis
arteriovenous fistula
arteriovenous graft
tunnelled central venous catheter
tunnelled central venous catheter
catheter into subclavian or internal jugular vein with tip in SVC orRA
–> 2 lumen blood exits (red), blood enters (blue)
pros and cons of tunnelled central venous catheter
pros = easy to insert + use immediatelt
cons = high risk of infections, can become blocked, stenosis thrombosis to central veins
gold standard for dialysis vascular access
arteriovenous fistula
pros + cons of arteriovenous fistula
pros = good flow, less likely to cause infection
con = requires surgery, maturation of 6-12weeks, limit flow to distal arm (steal syndrome), thrombosis/stenosis
what is steal syndrome
inadequate blood flow to limb distal to AV fistula -> distal ischaemia
(fistula “steals” blood)
haemofiafiltration
removal + replacement of >21L per session
increasingly convective in nature
why choose haemodiafiltration?
smoother, less symptomatic treatment that HD
enhance recovery time, improve survival
achievable + similar cost to HD
**BUT quality of life and restrictions*
cons of haemodiafiltration
BUT not efficient, min 4hrs 3x a week - poor quality of life
restrictions
- 1L per day - including food
- low salt
- low potassium
- low phosphate
types of renal transplant
decreased heart beating donors (DBD) - brain dead non-heart beating donors (DCD) live donation (altruistic) - paired
how are donors matched
HLA type A B C on chromosome 6
blood
kidney allocation steps
- paeds - any match
- 000 mismatch = ideal
- 100, 010 etc mismatch = favourable
- other match = unfavourable
signs of immediate graft function post renal transplant
good urine output
falling urea + creatinine
delayed graft function
post-transplant acute tubular necrosis
needs haemolyisis in meantime
10-30days
biopsy to check
side effect of tacrolimus
tremor
immunosupressive, life long post transplant
lifelong immunosupression post transplant
prednisolone
tacrolimus
mycophonolate
management of post-transplant lymphoproliferative disease`
reduce immunosuppression
sensitising events and their importance in renal transplants
blood transfusion, pregnancy/miscarriage, previous transplant
(previous formation of antibodies to non-self antigens can cause rejection)
acute anti-rejection treatments
pulsed IV methylprednisolone (ACR)
antithymocyre globulin
IV immunoglobulin
induction monoclonal antibodies post transplant
basiliximab or dacluzimab
block IL-2 receptors on CD4 T cells
(prevent rejection, not useful if already started)
MoA of glucocorticoids
inhibits lymphocyte proliferation, survival + activation
supress cytokines
calcineurin inhibitors in renal transplant
tacrolimus + ciclosporin
inhibit activation of T cells + prevent cytokine release
MoA of azathioprine + mycophonolate mofetil (MMF)
block purine synthesis - supress proliferation of lymphocytes
SE = leucopenia, GI upset, anaemia